223 related articles for article (PubMed ID: 33374989)
1. Real-World Experience with Bezlotoxumab for Prevention of Recurrence of
Escudero-Sánchez R; Ruíz-Ruizgómez M; Fernández-Fradejas J; García Fernández S; Olmedo Samperio M; Cano Yuste A; Valencia Alijo A; Díaz-Pollán B; Rodríguez Hernández MJ; Merino De Lucas E; Martín Segarra O; Sáez Bejar C; Armiñanzas Castillo C; Gutiérrez Gutiérrez B; Rodríguez-Pardo D; Ramos Martínez A; De La Torre Cisneros J; López-Medrano F; Cobo Reinoso J
J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33374989
[TBL] [Abstract][Full Text] [Related]
2. Real-world Experience of Bezlotoxumab for Prevention of
Hengel RL; Ritter TE; Nathan RV; Van Anglen LJ; Schroeder CP; Dillon RJ; Marcella SW; Garey KW
Open Forum Infect Dis; 2020 Apr; 7(4):ofaa097. PubMed ID: 32363211
[TBL] [Abstract][Full Text] [Related]
3. Genetic Association Reveals Protection against Recurrence of
Shen J; Mehrotra DV; Dorr MB; Zeng Z; Li J; Xu X; Nickle D; Holzinger ER; Chhibber A; Wilcox MH; Blanchard RL; Shaw PM
mSphere; 2020 May; 5(3):. PubMed ID: 32376702
[TBL] [Abstract][Full Text] [Related]
4. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
[TBL] [Abstract][Full Text] [Related]
5. Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies.
Giacobbe DR; Dettori S; Di Bella S; Vena A; Granata G; Luzzati R; Petrosillo N; Bassetti M
Infect Dis Ther; 2020 Sep; 9(3):481-494. PubMed ID: 32632582
[TBL] [Abstract][Full Text] [Related]
6. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, Safety, and Cost-effectiveness of Bezlotoxumab in Preventing Recurrent Clostridioides difficile Infection : Systematic Review and Meta-analysis.
Mohamed MFH; Ward C; Beran A; Abdallah MA; Asemota J; Kelly CR
J Clin Gastroenterol; 2024 Apr; 58(4):389-401. PubMed ID: 37395627
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of
Dubberke ER; Gerding DN; Kelly CP; Garey KW; Rahav G; Mosley A; Tipping R; Dorr MB
Open Forum Infect Dis; 2020 Jun; 7(6):ofaa157. PubMed ID: 32523972
[TBL] [Abstract][Full Text] [Related]
9. Bezlotoxumab in Patients with a Primary
Granata G; Schiavone F; Pipitone G
Antibiotics (Basel); 2022 Oct; 11(11):. PubMed ID: 36358149
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study.
Meschiari M; Cozzi-Lepri A; Cervo A; Granata G; Rogati C; Franceschini E; Casolari S; Tatarelli P; Giacobbe DR; Bassetti M; Pinna SM; De Rosa FG; Barchiesi F; Canovari B; Lorusso C; Russo G; Cenderello G; Cascio A; Petrosillo N; Mussini C
Int J Infect Dis; 2023 Jun; 131():147-154. PubMed ID: 37030653
[TBL] [Abstract][Full Text] [Related]
11. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
Madoff SE; Urquiaga M; Alonso CD; Kelly CP
Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes.
Johnson S; Citron DM; Gerding DN; Wilcox MH; Goldstein EJC; Sambol SP; Best EL; Eves K; Jensen E; Dorr MB
Clin Infect Dis; 2021 Nov; 73(9):e2616-e2624. PubMed ID: 32735653
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis.
Akiyama S; Yamada A; Komaki Y; Komaki F; Micic D; Sakuraba A
J Clin Gastroenterol; 2021 Jan; 55(1):43-51. PubMed ID: 32053529
[TBL] [Abstract][Full Text] [Related]
14. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence.
Johnson TM; Molina KC; Howard AH; Schwarz K; Allen L; Huang M; Bajrovic V; Miller MA
Clin Infect Dis; 2022 May; 74(9):1572-1578. PubMed ID: 34665248
[TBL] [Abstract][Full Text] [Related]
15. A time-to-event analysis of the exposure-response relationship for bezlotoxumab concentrations and CDI recurrence.
Yee KL; Kleijn HJ; Zajic S; Dorr MB; Wrishko RE
J Pharmacokinet Pharmacodyn; 2020 Apr; 47(2):121-130. PubMed ID: 32048107
[TBL] [Abstract][Full Text] [Related]
16. Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.
Goldstein EJC; Citron DM; Gerding DN; Wilcox MH; Gabryelski L; Pedley A; Zeng Z; Dorr MB
Clin Infect Dis; 2020 Aug; 71(4):1102-1105. PubMed ID: 31883370
[TBL] [Abstract][Full Text] [Related]
17. Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of
de la Villa S; Herrero S; Muñoz P; Rodríguez C; Valerio M; Reigadas E; Álvarez-Uría A; Alcalá L; Marín M; Olmedo M; Kestler M; Chamorro E; Bouza E
Open Forum Infect Dis; 2023 Feb; 10(2):ofad028. PubMed ID: 36776780
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review.
Thandavaram A; Channar A; Purohit A; Shrestha B; Patel D; Shah H; Hanna K; Kaur H; Alazzeh MS; Mohammed L
Cureus; 2022 Aug; 14(8):e27979. PubMed ID: 36120235
[TBL] [Abstract][Full Text] [Related]
19. Renal Impairment,
Golan Y; DuPont HL; Aldomiro F; Jensen EH; Hanson ME; Dorr MB
Open Forum Infect Dis; 2020 Jul; 7(7):ofaa248. PubMed ID: 32685606
[TBL] [Abstract][Full Text] [Related]
20. Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection.
Kelly CP; Poxton IR; Shen J; Wilcox MH; Gerding DN; Zhao X; Laterza OF; Railkar R; Guris D; Dorr MB
Clin Infect Dis; 2020 Jun; 71(1):81-86. PubMed ID: 31628838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
